Droperidol, marketed as Inapsine, is a butyrophenone — the same chemical class as haloperidol — with strong, fast-acting dopamine D2 blockade. It has been used since the 1970s in three main settings: surgical sedation and antiemesis in operating rooms, antiemesis for chemotherapy-related nausea, and acute agitation in psychiatric emergencies. In 2001, the FDA added a black box warning about QT prolongation and sudden cardiac death, which dramatically reduced its use. In the years since, growing evidence — particularly from emergency medicine — has revived interest in droperidol at lower doses, where the safety profile appears more favourable.
Droperidol is a fast-acting butyrophenone used in emergency settings for severe agitation and nausea, with a black box warning about QT prolongation that has been challenged by subsequent emergency medicine literature.
How it works
Strong dopamine D2 blockade in the central nervous system produces the antiemetic and antipsychotic effects. Onset is rapid — often within 10 to 30 minutes after intramuscular injection or intravenous administration. Half-life is about 2 hours. The fast onset and short duration are exactly what is needed in an emergency setting where a patient needs to be calmed quickly.
FDA-approved indication
Per the DailyMed droperidol label, droperidol is FDA-approved for the prevention and treatment of nausea and vomiting associated with surgical and diagnostic procedures. Use for acute agitation in psychiatric emergencies is off-label but well-established and widely practised in emergency medicine.
Use in acute agitation
In emergency departments and inpatient psychiatric settings, droperidol is sometimes given by intramuscular injection (commonly 2.5 to 5 mg) or intravenously for severe agitation. Onset is fast, and many patients are sufficiently calm within 30 minutes to allow further assessment. Compared with haloperidol, droperidol tends to be slightly faster-onset and slightly more sedating at equivalent doses. Compared with intramuscular benzodiazepines, droperidol is less likely to cause respiratory depression but more likely to cause acute dystonia.
The 2001 black box warning
In December 2001, the FDA added a black box warning to droperidol, citing 273 reports to MedWatch of QT prolongation and torsades de pointes, including 89 reports of cardiac arrest, between 1997 and 2001. Many of the reports involved doses higher than currently used or patients with multiple cardiac risk factors. The warning recommended ECG monitoring before and during use and restricted use to second-line situations. Droperidol use in the US dropped sharply.
The emergency medicine response
Emergency physicians, particularly through the American College of Emergency Physicians, pushed back. Multiple subsequent studies suggested that at the doses used in actual emergency practice (2.5 to 5 mg), QT prolongation was modest and clinically significant arrhythmia was rare. The American Academy of Emergency Medicine issued a position statement supporting droperidol's continued use. By the mid-2010s many emergency departments had reintroduced it, and supply problems related to manufacturing rather than clinical concerns drove much of its remaining absence from US practice.
People with prolonged baseline QT, congenital long QT syndrome, significant electrolyte abnormalities, or who are taking other QT-prolonging medications are at higher risk and require careful evaluation before droperidol is given.
Side effects
Cardiac
QT prolongation, especially at higher doses or in patients with risk factors. Rare torsades de pointes.
Movement effects
Acute dystonia (often within hours), parkinsonism, and akathisia. The akathisia after a single dose can be intensely uncomfortable and is sometimes mistaken for worsening agitation. Anticholinergic medications such as benztropine can be used as needed.
Sedation
Substantial. Patients are often noticeably drowsy after an intramuscular dose.
Hypotension
Particularly with intravenous administration. Blood pressure monitoring is standard.
Neuroleptic malignant syndrome
Rare but possible — fever, rigidity, autonomic instability, altered mental status.
Where droperidol fits in 2026
In emergency medicine, droperidol has substantially returned to use. Common situations include:
- Severe acute agitation in the emergency department, particularly when sedation needs to be fast
- Acute migraine refractory to other treatments
- Chemotherapy or post-operative nausea not responsive to first-line antiemetics
Outpatient psychiatric use is rare. The drug is essentially never prescribed for take-home daily use because of its short half-life, sedation, and cardiac monitoring requirements.
Practical context for patients and families
If a loved one was given droperidol in an emergency department, this means clinicians needed a fast-acting medication to manage severe agitation or nausea. The drug typically wears off within hours. Acute side effects (sedation, dry mouth, restlessness) usually resolve within a day. If new movement symptoms develop in the days afterward, contact the treating clinician — late-onset dystonia or akathisia can sometimes occur and is treatable.
Practical questions to ask
- Why was droperidol chosen rather than another medication?
- Was an ECG done before and after?
- Should I expect any movement side effects in the next 1–2 days?
- What follow-up is needed?
The big picture
Droperidol is a useful drug with a complicated history. The 2001 black box warning may have been an over-correction relative to the doses used in modern emergency practice. The drug remains valuable for rapid management of severe agitation and severe nausea, particularly in settings where ECG monitoring and post-administration observation are routine. It is not a long-term antipsychotic. Used wisely in the right setting, it has a clear place in the toolkit.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling, regulatory sources, and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.